Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
Open accessAbstract
BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. METHODS: We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor necrosis factor antagonists. Patients were randomly assigned (1:1) to groups given MEDI2070 (700 mg) or placebo intravenously at weeks 0 and 4. Patients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112. The CD Activity Index was used to measure disease activity. RESULTS: The primary outcome, clinical response (either a 100-point decrease in CD Activity Index score from baseline or clinical remission, defined as CD Activity Index score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7% receiving placebo (n = 60; absolute difference, 22.5%; 95% confidence interval, 5.6%-39.5%; P = .010). Clinical response at week 24 occurred in 53.8% of patients who continued to receive open-label MEDI2070 and in 57.7% of patients who had received placebo during the double-blind period and open-label MEDI2070 thereafter. The most common adverse events were headache and nasopharyngitis. Higher baseline serum concentrations of IL22, a cytokine whose expression is induced by IL23, were associated with greater likelihood of response to MEDI2070 compared with placebo. CONCLUSIONS: In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IL-17A has a key pathogenic role in murine arthritis models.
“IL-17A has been shown to have a key pathogenic role in murine arthritis models.”
From TH17 cell heterogeneity and its role in tissue inflammation (2023) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · see citing works
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,164 · see citing works
Self-citationDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152 · see citing works
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147 · see citing works
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135 · see citing works
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K. P., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,819 · see citing works
Colombel, J., Sandborn, W. J., Rutgeerts, P. J., Enns, R. A., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,239 · see citing works
Self-citationBaumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,205 · see citing works
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P. J., Fedorak, R. N., Lukáš, M., MacIntosh, D. G., Panaccione, R., Wolf, D. C., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,711 · see citing works
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P., Rutgeerts, P. J., Mason, D. H., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,141 · see citing works
Self-citationUstekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., BLANK, M. A., Johanns, J., Guzzo, C. A., Sands, B. E., Hanauer, S. B., Targan, S. R., Rutgeerts, P. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,132 · see citing works
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,039 · see citing works
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
Sandborn, W. J., Rutgeerts, P. J., Enns, R., Hanauer, S. B., Colombel, J., Panaccione, R., D’Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 961 · see citing works
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P. J., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 942 · see citing works
Self-citationIL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease
Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K., et al. (2008) · Gut · doi:10.1136/gut.2007.135053 · Cited by 571 · see citing works
Andoh, A., Zhang, Z., Inatomi, O., Fujino, S., Deguchi, Y., Araki, Y., Tsujikawa, T., Kitoh, K., Kim‐Mitsuyama, S., Takayanagi, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.071 · Cited by 480 · see citing works
Schmidt, C., Giese, T., Ludwig, B., Mueller-Molaian, I., Marth, T., Zeuzem, S., Meuer, S. C., & Stallmach, A. (2005) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200501000-00003 · Cited by 279 · see citing works
Schmechel, S., Konrad, A., Diegelmann, J., Glas, J., Wetzke, M., Paschos, E., Lohse, P., Göke, B., & Brand, S. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20315 · Cited by 188 · see citing works
The interleukin‐23 axis in intestinal inflammation
Ahern, P. P., Ízcue, A., Maloy, K. J., & Powrie, F. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00705.x · Cited by 180 · see citing works
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro
Brand, S., Dambacher, J., Beigel, F., Zitzmann, K., Heeg, M. H. J., Weiß, T. S., Prüfer, T., Olszak, T., Steib, C. J., Storr, M., et al. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00239.2006 · Cited by 122 · see citing works
Faubion, W. A., Fletcher, J. G., O’Byrne, S., Feagan, B. G., de Villiers, W. J. S., Salzberg, B. A., Plevy, S. E., Proctor, D. D., Valentine, J. F., Higgins, P., et al. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.354 · Cited by 108 · see citing works
Self-citationSandborn, W. J., Colombel, J., Schreiber, S., Plevy, S. E., Pollack, P. F., Robinson, A. M., Chao, J., & Mulani, P. M. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21328 · Cited by 80 · see citing works
Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease
Dige, A. K., Støy, S. H., Rasmussen, T. K., Kelsen, J., Hvas, C. L., Sandahl, T. D., Dahlerup, J. F., Deleuran, B. W., & Agnholt, J. S. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.06.015 · Cited by 63 · see citing works
Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
Cayatte, C., Joyce-Shaikh, B., Vega, F., Boniface, K., Grein, J., Murphy, E., Blumenschein, W. M., Chen, S., Malinao, M.-C., Basham, B., et al. (2012) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2012.2 · Cited by 52 · see citing works
Ge, M., Durham, L. K., Meyer, R. D., Xie, W., & Thomas, N. (2011) · Drug Information Journal · doi:10.1177/009286151104500409 · Cited by 39 · see citing works
Preclinical development of AMG 139, a human antibody specifically targeting IL ‐23
Köck, K., Pan, W., Gow, J. M., Horner, M. J., Gibbs, J. P., Colbert, A., Goletz, T. J., Newhall, K. J., Rees, W. A., Sun, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12904 · Cited by 32 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Robert Hardi (Metropolitan Gastroenterology Group, Chevy Chase, MD), John Hanson (Charlotte Gastroenterology & Hepatology, Charlotte, NC), Peter Higgins (University of Michigan Health Care System, Ann Arbor, MI), David Kerman (University of Miami, Miami, FL), Bruce Sands (Icahn School of Medicine at Mount Sinai, New York, NY), Cynthia Schaeffer (Precision Research Institute, Chula Vista, CA), Ellen Scherl (Weill Medical College, New York, NY), Shahriar Sedghi (Gastroenterology Associates of Central Georgia, Macon, GA), Ira Shafran (Shafran Gastroenterology Center, Winter Park, FL), and John Weber (Troy Internal Medicine PC, Troy, MI). Ethics Committees/Internal Review Boards That Approved the Study Protocol (With Study Approval Numbers) Canada: IRB Services, Autora, ON; Mount Sinai Hospital Ethics Committee, Toronto, ON; Ontario Hall Queens Uni- versity, Kingston, ON; Ottawa Health Science Network Research Ethics Board, Ottawa, ON; University of Alberta Health Research Ethics Board, Edmonton, AB; Western University REB, London, ON; Protocol approval numbers do not apply in Canada. Czech Republic: Ethics Committee FN Hradec Kralove, Hradec Kralove (201302 D02M); Eticka Komise ISCARE, Praha 7 (52/a); Eticka Komise Fakultni Nemocnice Kra- lovske Vinohrady, Praha 10 (KH/76/0/2012);
Cited by
Sorted by citations
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,424 · see citing works
Self-citationPathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295 · see citing works
Roda, G., Ng, S. C., Kotze, P. G., ARGOLLO, M. C., Panaccione, R., Spinelli, A., Kaser, A., Peyrin‐Biroulet, L., & Danese, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0156-2 · Cited by 1,067 · see citing works
Self-citationCytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. M. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750 · see citing works
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 703 · see citing works
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 477 · see citing works
D’Haens, G., Panaccione, R., Baert, F., Bossuyt, P. J., Colombel, J., Danese, S., Dubinsky, M. C., Feagan, B. G., Hisamatsu, T., Lim, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00467-6 · Cited by 434 · see citing works
Self-citationMarques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., da Silva, I. C. B., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 400 · see citing works
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Berre, C. L. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 363 · see citing works
TH17 cell heterogeneity and its role in tissue inflammation
Schnell, A., Littman, D. R., & Kuchroo, V. K. (2023) · Nature Immunology · doi:10.1038/s41590-022-01387-9 · Cited by 286 · see citing works
Innate Lymphoid Cells in Mucosal Immunity
Panda, S. K., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00861 · Cited by 276 · see citing works
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Verstockt, B., Salas, A., Sands, B. E., Abraham, C., Leibovitzh, H., Neurath, M. F., Casteele, N. V., Danese, S., D’Haens, G., Eckmann, L., et al. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00768-1 · Cited by 266 · see citing works
Self-citationSchmitt, H., Billmeier, U., Dieterich, W., Räth, T., Sonnewald, S., Reid, S., Hirschmann, S., Hildner, K., Waldner, M. J., Mudter, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315671 · Cited by 261 · see citing works
Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies
Ahluwalia, B., Moraes, L., Magnusson, M. K., & Öhman, L. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1447597 · Cited by 245 · see citing works
Kamata, M., & Tada, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051690 · Cited by 238 · see citing works
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
Sandborn, W. J., Ferrante, M., Bhandari, B. R., Berliba, E., Feagan, B. G., Hibi∥, T., TUTTLE, J. L., Klekotka, P. A., Friedrich, S. W., Durante, M., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.043 · Cited by 232 · see citing works
Self-citationTumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
Ruder, B., Atreya, R., & Becker, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081887 · Cited by 228 · see citing works
“Indeed, recent studies have shown high response rates in anti-TNFα experienced CD patients using specific IL-23 p19 blockers [173,174].”
BackgroundIL-23 in inflammatory bowel diseases and colon cancer
Neurath, M. F. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.12.002 · Cited by 216 · see citing works
Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus
Katsuyama, T., Tsokos, G. C., & Moulton, V. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01088 · Cited by 213 · see citing works
Role of the IL23/IL17 Pathway in Crohn’s Disease
Schmitt, H., Neurath, M. F., & Atreya, R. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622934 · Cited by 208 · see citing works
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
Sandborn, W. J., D’Haens, G., Reinisch, W., Panés, J., Chan, D., Gonzalez, S., Weisel, K., Germinaro, M., Frustaci, M. E., Yang, Z., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.01.047 · Cited by 207 · see citing works
Self-citationImmunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics
Lu, Q., Yang, M.-F., Liang, Y.-J., Xu, J., Xu, H.-M., Nie, Y.-Q., Wang, L.-S., Yao, J., & Li, D.-F. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s353038 · Cited by 211 · see citing works
Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., On, S. C. J., Vekaria, A. S., Traidl‐Hoffmann, C., Singer, G., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.028 · Cited by 200 · see citing works
Schreiber, S., Colombel, J., Feagan, B. G., Reich, K., Deodhar, A. A., McInnes, I. B., Porter, B. O., Gupta, A. D., Pricop, L., & Fox, T. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214273 · Cited by 195 · see citing works
Self-citationCytokines in inflammatory bowel diseases – Update 2020
Leppkes, M., & Neurath, M. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104835 · Cited by 194 · see citing works
Serum Biomarkers for Inflammatory Bowel Disease
Chen, P., Zhou, G., Lin, J., Li, L., Zeng, Z., Chen, M., & Zhang, S. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00123 · Cited by 193 · see citing works
Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut
Mahapatro, M., Erkert, L., & Becker, C. (2021) · Cells · doi:10.3390/cells10010111 · Cited by 179 · see citing works
New Therapeutics for Ulcerative Colitis
Hirten, R. P., & Sands, B. E. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120048 · Cited by 177 · see citing works
Self-citationNew treatment options for inflammatory bowel diseases
Verstockt, B., Ferrante, M., Vermeire, S., & Assche, G. V. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1449-z · Cited by 169 · see citing works
Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease
Uhlig, H. H., & Powrie, F. M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053055 · Cited by 170 · see citing works
Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., & Offidani, A. (2021) · Biomedicines · doi:10.3390/biomedicines9111511 · Cited by 159 · see citing works
Inflammatory cytokines: from discoveries to therapies in IBD
Marafini, I., Sedda, S., Dinallo, V., & Monteleone, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1652267 · Cited by 154 · see citing works
Sewell, G. W., & Kaser, A. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac034 · Cited by 155 · see citing works
The role of Th17 cells in inflammatory bowel disease and the research progress
Chen, L., Ruan, G., Cheng, Y., Yi, A., Chen, D., & Wei, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055914 · Cited by 155 · see citing works
Novel and Emerging Therapies for Inflammatory Bowel Disease
Al‐Bawardy, B., Shivashankar, R., & Proctor, D. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.651415 · Cited by 153 · see citing works
The involvement of TH17 cells in the pathogenesis of IBD
Jiang, P., Zheng, C., Xiang, Y., Malik, S., Su, D., Xu, G., & Zhang, M. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.005 · Cited by 150 · see citing works
Powell, N., Pantazi, E. D., Pavlidis, P., Tsakmaki, A., Li, K., Yang, F., Parker, A., Pin, C., Cozzetto, D., Minns, D., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318483 · Cited by 146 · see citing works
Noviello, D., Mager, R., Roda, G., Borroni, R. G., Fiorino, G., & Vetrano, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611256 · Cited by 148 · see citing works
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
Na, S., & Moon, W. (2019) · Gut and Liver · doi:10.5009/gnl19019 · Cited by 132 · see citing works
Immunology of IL-12: An update on functional activities and implications for disease
Ullrich, K. A.-M., Schulze, L. L., Paap, E.-M., Müller, T. M., Neurath, M. F., & Zundler, S. (2020) · EXCLI journal · doi:10.17179/excli2020-3104 · Cited by 137 · see citing works
Interrogating host immunity to predict treatment response in inflammatory bowel disease
Digby-Bell, J. L., Atreya, R. N., Monteleone, G., & Powell, N. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0228-5 · Cited by 127 · see citing works
Wang, Y., Mumm, J. B., Herbst, R., Kolbeck, R., & Wang, Y. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700152 · Cited by 125 · see citing works
Fine, S., Papamichael, K., & Cheifetz, A. S. (2019) · PubMed Central · Cited by 125 · see citing works
Aschenbrenner, D., Quaranta, M., Banerjee, S., Ilott, N., Jansen, J., Steere, B., Chen, Y.-H., Ho, S., Cox, K., Arancibia-Cárcamo, C. V., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321731 · Cited by 123 · see citing works
Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies
Zhao, J., Lu, Q., Liu, Y., Shi, Z., Hu, L., Zeng, Z., Tu, Y., Xiao, Z., & Xu, Q. (2021) · Journal of Immunology Research · doi:10.1155/2021/8816041 · Cited by 126 · see citing works
Eftychi, C., Schwarzer, R., Vlantis, K., Wachsmuth, L., Basic, M., Wagle, P., Neurath, M. F., Becker, C., Bleich, A., & Pasparakis, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.008 · Cited by 118 · see citing works
New biologics and small molecules in inflammatory bowel disease: an update
Sabino, J., Verstockt, B., Vermeire, S., & Ferrante, M. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819853208 · Cited by 118 · see citing works
Molecular control of pathogenic Th17 cells in autoimmune diseases
Wu, B., & Wan, Y. Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106187 · Cited by 118 · see citing works
Paramsothy, S., Rosenstein, A. K., Mehandru, S., & Colombel, J. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0050-3 · Cited by 115 · see citing works
Weinstein, J. E., & Pepple, K. L. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000466 · Cited by 113 · see citing works
Shifting the focus – the primary role of IL ‐23 in psoriasis and other inflammatory disorders
Gooderham, M., Papp, K. A., & Lynde, C. W. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14868 · Cited by 109 · see citing works
Atreya, R. N., & Neurath, M. F. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30265-6 · Cited by 104 · see citing works
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Almradi, A., Hanžel, J., Sedaño, R., Parker, C. E., Feagan, B. G., Ma, C., & Jairath, V. (2020) · BioDrugs · doi:10.1007/s40259-020-00451-w · Cited by 103 · see citing works
Self-citationBiological therapies in inflammatory bowel disease: Beyond anti-TNF therapies
Katsanos, K. H., Papamichael, K., Feuerstein, J. D., Christodoulou, D. K., & Cheifetz, A. S. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.004 · Cited by 99 · see citing works
Inflammatory bowel disease: between genetics and microbiota
Younis, N. K., Zarif, R., & Mahfouz, R. A. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05318-5 · Cited by 99 · see citing works
He, Z., Chen, L., Catalan‐Dibene, J., Bongers, G., Faith, J. J., Suebsuwong, C., DeVita, R. J., Shen, Z., Fox, J. G., Lafaille, J. J., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.04.015 · Cited by 96 · see citing works
Old and New Lymphocyte Players in Inflammatory Bowel Disease
Giuffrida, P., Corazza, G. R., & Sabatino, A. D. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4892-4 · Cited by 94 · see citing works
Blockade of IL-23: What is in the Pipeline?
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab185 · Cited by 93 · see citing works
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91 · see citing works
Emerging Therapies for Inflammatory Bowel Disease
Weisshof, R., Jurdi, K. E., Zmeter, N., & Rubin, D. T. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0795-9 · Cited by 89 · see citing works
Chyuan, I., & Lai, J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113928 · Cited by 87 · see citing works
Personalised medicine in Crohn's disease
Noor, N. M., Verstockt, B., Parkes, M., & Lee, J. C. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30340-1 · Cited by 83 · see citing works
The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease
Korta, A., Kula, J., & Gomułka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210172 · Cited by 80 · see citing works
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More
Misselwitz, B., Juillerat, P., Sulz, M. C., Siegmund, B., Brand, S., & on behalf of Swiss IBDnet, A. O. W. G. O. T. S. S. O. G. (2020) · Digestion · doi:10.1159/000507782 · Cited by 77 · see citing works
Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
Bourgonje, A. R., Ungaro, R. C., Mehandru, S., & Colombel, J. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.036 · Cited by 77 · see citing works
Verstockt, B., Noor, N. M., Marigorta, U. M., Pavlidis, P., Deepak, P., Ungaro, R. C., Fiocchi, C., Torres, J., & Scharl, M. M. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab050 · Cited by 75 · see citing works
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Pagnini, C., Pizarro, T. T., & Cominelli, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00671 · Cited by 75 · see citing works
Schreiner, P., Neurath, M. F., Ng, S. C., El-Omar, E. M., Sharara, A. I., Kobayashi, T., Hisamatsu, T., Hibi∥, T., & Rogler, G. (2019) · Inflammatory Intestinal Diseases · doi:10.1159/000500721 · Cited by 75 · see citing works
IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
Atreya, R. N., & Neurath, M. F. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac007 · Cited by 74 · see citing works
Review article: emerging drug therapies in inflammatory bowel disease
Grossberg, L. B., Papamichael, K., & Cheifetz, A. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16785 · Cited by 77 · see citing works
Aggeletopoulou, I., Assimakopoulos, S. F., Konstantakis, C., & Triantos, C. K. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i36.4093 · Cited by 74 · see citing works
Two distinct colonic CD14+ subsets characterized by single-cell RNA profiling in Crohn's disease
Chapuy, L., Bsat, M., Sarkizova, S., Rubio, M., Therrien, A., Wassef, E., Bouin, M., Orlicka, K., Weber, A. M., Hacohen, N., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-018-0126-0 · Cited by 73 · see citing works
Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
Pepple, K. L., & Lin, P. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.05.014 · Cited by 73 · see citing works
Biomarkers for Personalizing IBD Therapy: The Quest Continues
Atreya, R. N., & Neurath, M. F. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.026 · Cited by 71 · see citing works
Advances in understanding the role of cytokines in inflammatory bowel disease
Bevivino, G., & Monteleone, G. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1503053 · Cited by 71 · see citing works
Vébr, M., Pomahačová, R., Sýkora, J., & Schwarz, J. (2023) · Biomedicines · doi:10.3390/biomedicines11123229 · Cited by 71 · see citing works
Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease
Duijvestein, M., Battat, R. J., Casteele, N. V., D’Haens, G., Sandborn, W. J., Khanna, R., Jairath, V., & Feagan, B. G. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0175-1 · Cited by 67 · see citing works
Self-citationSandborn, W. J., Ferrante, M., Bhandari, B. R., Berliba, E., Hibi∥, T., D’Haens, G., TUTTLE, J. L., Krueger, K. A., Friedrich, S. W., Durante, M., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.028 · Cited by 66 · see citing works
Self-citationNew targets in inflammatory bowel disease therapy: 2021
Cohen, N. A., & Rubin, D. T. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000740 · Cited by 66 · see citing works
Bacterial Translocation as Inflammatory Driver in Crohn’s Disease
Linares, R., Francés, R., Gutiérrez, A., & Juanola, O. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.703310 · Cited by 66 · see citing works
How Do We Predict a Patient’s Disease Course and Whether They Will Respond to Specific Treatments?
Verstockt, B., Parkes, M., & Lee, J. C. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.245 · Cited by 60 · see citing works
Sun, R., Hedl, M., & Abraham, C. (2019) · Gut · doi:10.1136/gutjnl-2018-316830 · Cited by 59 · see citing works
Anti-interleukin-23 agents for the treatment of ulcerative colitis
Hanžel, J., & D’Haens, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1697227 · Cited by 59 · see citing works
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
Bretto, E., Ribaldone, D. G., Caviglia, G. P., Saracco, G. M., Bugianesi, E., & Frara, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082249 · Cited by 58 · see citing works
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
Smith, K. A., Pulsipher, A., Gabrielsen, D. A., & Alt, J. A. (2018) · American Journal of Rhinology and Allergy · doi:10.1177/1945892418787132 · Cited by 58 · see citing works
Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
Bravo, A., & Kavanaugh, A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0285-8 · Cited by 54 · see citing works
Targeting IL-23 for IBD: Rationale and Progress to Date
Vuyyuru, S. K., Shackelton, L. M., Hanžel, J., Ma, C., Jairath, V., & Feagan, B. G. (2023) · Drugs · doi:10.1007/s40265-023-01882-9 · Cited by 54 · see citing works
Self-citationStevens, T. W., Matheeuwsen, M., Lönnkvist, M. H., Parker, C. E., Wildenberg, M. E., Gecse, K. B., & D’Haens, G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15033 · Cited by 54 · see citing works
Ma, C., Hussein, I. M., Al-Abbar, Y. J., Panaccione, R., Fedorak, R. N., Parker, C. E., Nguyen, T. M., Khanna, R., Siegel, C. A., Peyrin‐Biroulet, L., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.02.051 · Cited by 53 · see citing works
Self-citationImmunotherapy in inflammatory bowel disease: Novel and emerging treatments
Catalán‐Serra, I., & Brenna, Ø. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1461297 · Cited by 54 · see citing works
Kashani, A., & Schwartz, D. A. (2019) · PubMed Central · Cited by 48 · see citing works
Ma, C., Sandborn, W. J., D’Haens, G., Zou, G., Stitt, L., Singh, S., Ananthakrishnan, A. N., Dulai, P. S., Khanna, R., Jairath, V., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.021 · Cited by 49 · see citing works
Self-citationMa, C., Battat, R. J., Parker, C. E., Khanna, R., Jairath, V., & Feagan, B. G. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1563481 · Cited by 48 · see citing works
Self-citationThe Role of IL-23 Inhibitors in Crohn’s Disease
Fanizza, J., D’Amico, F., Lusetti, F., Fasulo, E., Allocca, M., Furfaro, F., Zilli, A., Parigi, T. L., Radice, S., Peyrin‐Biroulet, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010224 · Cited by 47 · see citing works
Self-citationBloemendaal, F. M., Koelink, P. J., van Schie, K. A., Rispens, T., Peters, C. P., Buskens, C. J., van der Bilt, J. D. W., Bemelman, W. A., Korf, H., Sabino, J., et al. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy075 · Cited by 47 · see citing works
Bassolas-Molina, H., Raymond, E. L., Labadia, M. E., Wahle, J. A., Ferrer-Picón, E., Panzenbeck, M., Zheng, J., Harcken, C., Hughes, R. O., Turner, M. S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02307 · Cited by 47 · see citing works
Interleukin 23 and autoimmune diseases: current and possible future therapies
Abdo, A. I. K., & Tye, G. J. (2020) · Inflammation Research · doi:10.1007/s00011-020-01339-9 · Cited by 45 · see citing works
Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases
Retnakumar, S. V., & Muller, S. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.03.002 · Cited by 44 · see citing works
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
Privitera, G., Pugliese, D., Rapaccini, G. L., Gasbarrini, A., Armuzzi, A., & Guidi, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040853 · Cited by 44 · see citing works
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies
Cozzi, G., Scagnellato, L., Lorenzin, M., Savarino, E. V., Zingone, F., Ometto, F., Favero, M., Doria, A., Vavricka, S. R., & Ramonda, R. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00984-8 · Cited by 43 · see citing works
- Authors
- Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., Li, J., Klekotka, P., Morehouse, C., Pulkstenis, E., Drappa, J., van der Merwe, R., & Gasser, R. A.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Western University (CA)
- University of Michigan (US)
- Amgen (United States) (US)
- Corresponding author
- Sands, Bruce E.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 153
- Issue
- 1
- Pages
- 77-86.e6
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2604523348
- Cited by
- 279
- References
- 26
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 25 · 2023: 36 · 2022: 35 · 2021: 34 · 2020: 35 · 2019: 50 · 2018: 40 · 2017: 5
- FWCI
- 23.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Zenodo (CERN European Organization for Nuclear Research) (public-domain)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- interleukin-23 inhibition, Crohn's disease, monoclonal antibodies, clinical response, clinical remission, CD activity index, IL-22, treatment safety, biologic therapy
- MeSH terms
- Interleukin-22, Adult, Antibodies, Monoclonal, Crohn Disease, Double-Blind Method, Female, Headache, Humans, Interleukins, Male, Middle Aged, Nasopharyngitis, Severity of Illness Index, Treatment Outcome, Retreatment, Interleukin-23, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
